Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia

Stopped early · Phase 2

Conditions studied: High Grade Squamous Intraepithelial Neoplasia, Stage 0 Uterine Corpus Cancer

In brief

This randomized phase II trial is studying how well megestrol works in treating patients with endometrial neoplasia or endometrial hyperplasia. Estrogen can cause the growth of endometrial cancer cells. Hormone therapy using megestrol may fight endometrial cancer by blocking the use of estrogen by the abnormal cells.

Key facts

Study ID

NCT00503581

Run by

Gynecologic Oncology Group

People needed

9

Starts

2007-07-01

Last updated by the study team

2020-11-03

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have a diagnosis of atypical endometrial hyperplasia (AEH) or endometrial intraepithelial neoplasia (EIN) diagnosed by dilatation and curettage (D\&C), Novak curettage, Vabra aspirate, or Pipelle endometrial biopsy at the enrolling institution within 12 weeks of enrollment
• Patients must desire uterine retention for duration of study (18 months or after 3rd biopsy) if they remain EIN negative (-); patients are allowed to attempt pregnancy after their initial post-treatment biopsy without it being a major protocol violation
• Patients must have a GOG performance status of 0, 1, or 2
• White blood cell (WBC) >= 3000
• Platelets >= 100,000
• Granulocytes >= 1,500
• Creatinine =< 2
• Bilirubin =< 1.5 x institutional upper limit normal
• Serum glutamic oxaloacetic transaminase (SGOT) =< 3 x institutional upper limit normal
• Alkaline phosphatase =< 3 x institutional upper limit normal
• Patients of child-bearing potential must have a negative serum pregnancy test prior to starting study drug and prior to each biopsy if capable of becoming pregnant (and at the discretion of the referring physician)
• Patients of childbearing potential must use appropriate non-hormonal contraception while on study medication
• Patients who have met the pre-entry requirements
• Patients must have signed an approved informed consent and authorization permitting release of personal health information

You may not qualify if…

• Patients with a GOG performance status of 3 or 4
• Patients with recognized endometrial carcinoma
• Patients with current or prior history of breast cancer
• Patients with invasive malignancies, with the exception of nonmelanoma skin cancer who had (or have) any evidence of the other cancer present within the past 5 years or whose previous cancer treatment contraindicates this protocol therapy
• Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded
• Patients who have received prior chemotherapy for any abdominal or pelvic tumor are excluded
• Patients who are pregnant or lactating
• Patients with a history of thrombophlebitis, thromboembolic phenomena, or cerebrovascular disorders within the past 5 years
• Patients under 18 years of age

Where it is running

• Kaiser Permanente Los Angeles Medical Center — Los Angeles, California, United States
• Olive View-University of California Los Angeles Medical Center — Sylmar, California, United States
• Hartford Hospital — Hartford, Connecticut, United States
• Saint Francis Hospital and Medical Center — Hartford, Connecticut, United States
• The Hospital of Central Connecticut — New Britain, Connecticut, United States
• Memorial University Medical Center — Savannah, Georgia, United States
• Saint Anthony's Health — Alton, Illinois, United States
• Rush - Copley Medical Center — Aurora, Illinois, United States
• Northwestern University — Chicago, Illinois, United States
• Joliet Oncology-Hematology Associates Limited — Joliet, Illinois, United States
• Good Samaritan Regional Health Center — Mount Vernon, Illinois, United States
• Carle Clinic-Urbana Main — Urbana, Illinois, United States
• Elkhart Clinic — Elkhart, Indiana, United States
• Michiana Hematology Oncology PC-Elkhart — Elkhart, Indiana, United States
• Elkhart General Hospital — Elkhart, Indiana, United States
• Indiana University/Melvin and Bren Simon Cancer Center — Indianapolis, Indiana, United States
• Community Howard Regional Health — Kokomo, Indiana, United States
• IU Health La Porte Hospital — La Porte, Indiana, United States
• Franciscan Saint Anthony Health-Michigan City — Michigan City, Indiana, United States
• Michiana Hematology Oncology PC-Mishawaka — Mishawaka, Indiana, United States
• Saint Joseph Regional Medical Center-Mishawaka — Mishawaka, Indiana, United States
• Michiana Hematology Oncology PC-Plymouth — Plymouth, Indiana, United States
• Memorial Hospital of South Bend — South Bend, Indiana, United States
• Michiana Hematology Oncology PC-South Bend — South Bend, Indiana, United States
• South Bend Clinic — South Bend, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.